# ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

> **NCT06787144** · PHASE1 · RECRUITING · sponsor: **Enliven Therapeutics** · enrollment: 21 (estimated)

## Conditions studied

- CML (Chronic Myelogenous Leukemia)
- Chronic Phase CML

## Interventions

- **DRUG:** ELVN-001

## Key facts

- **NCT ID:** NCT06787144
- **Lead sponsor:** Enliven Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-23
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06787144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06787144, "ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06787144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*